Inhibitor Therapeutics, Inc.
INTI · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8,577 | $7,214 | $8,616 | $10,357 |
| - Cash | $2,977 | $3,738 | $4,322 | $5,607 |
| + Debt | $72 | $78 | $84 | $0 |
| Enterprise Value | $5,672 | $3,554 | $4,379 | $4,750 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$712 | -$696 | -$675 | -$1,422 |
| % Margin | – | – | – | – |
| Net Income | -$712 | -$660 | -$633 | -$1,422 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.004 | -0.004 | -0.004 | -0.008 |
| % Growth | -7.9% | -2.7% | 55.4% | – |
| Operating Cash Flow | -$761 | -$584 | -$1,285 | -$771 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$761 | -$584 | -$1,285 | -$771 |